Johnson and Johnson’s Ortho Biotech has informed the FDA of preliminary safety findings from a clinical trial conducted in Germany investigating the use of Procrit (epoetin alfa) to treat acute ischemic stroke. The clinical trial utilised doses of Procrit that were considerably higher than the doses recommended for the treatment of anemia as described in [...]
Entries Tagged as 'strategy'
Procrit linked to deaths in stroke patients
October 1st, 2008 · No Comments · Epoetin alfa, FDA, Food and Drug Administration, competitive intelligence, pharma, strategy
Tags:
Abiraterone and prostate cancer
September 2nd, 2008 · No Comments · Cougar, abiraterone, biotechnology, cancer, competitive intelligence, oncology, pharma, prostate, strategy
One drug that has been tearing up the newsfeed this year is abiraterone, a novel drug in phase II trials for prostate cancer. In February, data was presented at ASCO’s Genito-urinary satellite meeting that looked promising. Dr D.C. Danila and researchers from Memorial Sloan Kettering reported a small phase II trial in castration resistant metastatic [...]
Tags:
Improving survival in Liver Cancer – at what cost?
July 28th, 2008 · No Comments · cancer, competitive intelligence, health, liver cancer, market trends, oncology, pharma, strategy
No effective therapy is available for advanced hepatocellular carcinoma (liver cancer), it’s a terminal condition. Over 18,000 people typically die from it in the USA each year. It is much more common in Africa and East Asia where the risk of infection from Hepatitis B and C is much higher, which are associated with increased [...]
Tags: